Platelet-Activating Antibody Detection with Releasate Flow Cytometry
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic tests for heparin-induced thrombocytopenia (HIT) lack specificity and efficiency, leading to inaccurate diagnosis and increased hospitalization and bleeding risks due to the use of radioactivity and labor-intensive methods like the serotonin release assay (SRA) and PF4-based ELISA.
Innovation Solution
A method involving the preparation of a platelet releasate from normal subjects, combining it with test subject's blood, and measuring platelet activation using fluorescence-based flow cytometry to identify pathogenic antibodies, including heparin-induced thrombocytopenia antibodies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If the serotonin release assay (SRA) is used for HIT diagnosis, then measurement precision is improved, but device complexity and ease of operation deteriorate due to radioactivity use, labor intensiveness, and technical demands
Solution Approach 1:
The patent extracts the essential functional component (platelet releasate containing activating factors) from the complex SRA system, eliminating the need for radioactivity and complex procedures while retaining diagnostic capability through a simplified flow cytometry-based approach
Solution Approach 2:
The patent replaces the mechanical/manual-intensive SRA procedure with an automated flow cytometry system that uses fluorescent markers to detect platelet activation, substituting manual radioactivity-based measurement with automated optical detection
2Ease of operation
If the PF4-based ELISA is used for HIT diagnosis, then ease of operation is improved, but measurement precision deteriorates due to lack of specificity
Solution Approach 1:
The patent introduces platelet releasate as an intermediary substance that mediates between the simple ELISA format and the specific platelet activation detection needed for accurate HIT diagnosis, allowing straightforward operation while maintaining high specificity
Solution Approach 2:
The patent changes the detection parameter from general antibody presence (ELISA) to specific platelet activation markers (fluorescently labeled antibodies binding to activated platelet surface markers), thereby improving diagnostic specificity while maintaining operational simplicity
3Reliability
If conventional HIT diagnostic methods are used, then diagnosis can be performed, but loss of time increases due to additional hospitalization and treatment delays
Solution Approach 1:
The patent performs preliminary preparation of platelet releasate that can be stored and used immediately for testing, eliminating the need for fresh platelet preparation and enabling rapid diagnosis without extended hospitalization
Solution Approach 2:
The patent skips the lengthy and complex procedural steps of traditional SRA or PF4-ELISA by using a streamlined flow cytometry assay that delivers results quickly, reducing diagnostic time and enabling prompt clinical decision-making
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Provides a timely and accurate diagnosis of HIT by identifying platelet-activating antibodies, reducing morbidity and hospitalization costs, and minimizing bleeding risks.
Implementation Method 1
combining a platelet releasate from one or more normal subjects with platelets from one or more normal subjects, and with the blood sample from the subject suspected of having platelet-activating antibodies and incubating the combination for a period of time; and measuring platelet activation
Implementation Method 2
measuring platelet activation comprises analyzing the expression of cell surface markers that are expressed upon platelet activation using fluorescence-based flow cytometry
Data Source
AI summary
Described is a method for identifying pathogenic platelet-activating antibodies in a subject's blood and particularly antibodies implicated in heparin-induced thrombocytopenia (HIT) which comprises the preparation of a platelet releasate from a normal subject's platelets, the combination of the platelet release with a normal subject's platelets, a test subject's blood sample, and analyzing the sample for platelet activation.